Xie Huan, Li Yirong, Li Xinran
Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Hubei Provincial Clinical Research Center for Molecular Diagnostics, Wuhan, China.
Int J Med Sci. 2025 Jun 12;22(12):2932-2943. doi: 10.7150/ijms.109506. eCollection 2025.
The gene encodes the class IA PI3K regulatory subunit p85α, which is frequently altered in cancer. functions as a tumor suppressor by stabilizing and inhibiting the catalytic activity of p110, and it directly binds to and enhances the activity of the PTEN lipid phosphatase. Aberrations in the gene are associated with poor prognosis in cancer; available data underscore the significant role of mutations in mediating tumorigenesis by promoting the signaling of the PI3K/AKT/mTOR pathway. Moreover, copy number variations, driver mutations, and epigenetic alterations in contribute to tumorigenesis and progression through distinct mechanisms. This article reviews the cancer-promoting effects of gene aberrations across major cancer types and elucidates their underlying mechanisms. It also discusses the targeted therapies for related aberrations, aiming to provide a comprehensive understanding of the dynamic interplay of in cancer, thereby advancing precision medicine and the development of targeted interventions.
该基因编码IA类PI3K调节亚基p85α，其在癌症中经常发生改变。它通过稳定和抑制p110的催化活性发挥肿瘤抑制作用，并且直接结合并增强PTEN脂质磷酸酶的活性。该基因的异常与癌症预后不良相关；现有数据强调了该基因突变在通过促进PI3K/AKT/mTOR信号通路介导肿瘤发生中的重要作用。此外，该基因的拷贝数变异、驱动突变和表观遗传改变通过不同机制促进肿瘤发生和进展。本文综述了该基因异常在主要癌症类型中的促癌作用，并阐明了其潜在机制。还讨论了针对相关异常的靶向治疗，旨在全面了解该基因在癌症中的动态相互作用，从而推动精准医学和靶向干预的发展。
